Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies.

Jan-Henrik Mikesch1, Horst Buerger, Ronald Simon

  • 1Department of Haematology-Oncology, University Hospital, Westf.-Wilhelms-Univ. Münster, Germany.

Biochimica Et Biophysica Acta
|June 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beta-blocker use and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.

Annals of hematology·2026
Same author

Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.

The Lancet. Haematology·2026
Same author

Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.

Blood neoplasia·2026
Same author

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

American journal of hematology·2026
Same author

Relapse after allogeneic hematopoietic stem cell transplantation in patients with active acute myeloid leukemia.

Leukemia research·2025
Same author

Immune reconstitution in AML and MDS patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with treosulfan- or TBI-based conditioning.

Bone marrow transplantation·2025

Decay-accelerating factor (DAF, CD55) is a complement inhibitor also promoting cancer growth, invasion, and metastasis. Targeting DAF offers a promising strategy for novel cancer therapies.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Decay-accelerating factor (DAF, CD55) is a key regulator of the complement system.
  • DAF is frequently overexpressed in various malignant tumors, suggesting roles beyond immune regulation.

Purpose of the Study:

  • To explore the multifaceted roles of DAF in cancer progression.
  • To review DAF's potential as a diagnostic and therapeutic target in oncology.

Main Methods:

  • Literature review of DAF's functions in tumorigenesis, metastasis, and therapeutic strategies.
  • Analysis of DAF's involvement in oncogenic pathways and receptor interactions (e.g., CD97).

Main Results:

  • DAF promotes tumor growth, inhibits complement-mediated lysis, and facilitates evasion of apoptosis.

Related Experiment Videos

  • DAF contributes to neoangiogenesis, invasiveness, motility, and metastasis through tyrosine kinase pathways.
  • DAF's interaction with CD97 and its role in autocrine loops are highlighted.

    • Conclusions:

    • DAF exhibits significant oncogenic functions extending beyond its complement-inhibitory role.
    • Targeting DAF, through antibodies or vaccination, represents a viable therapeutic approach for cancer treatment.